Home > Dermatology > AAD 2019 > Psoriasis and Biologics: The Beat Goes On > Psoriasis and Biologics: The Beat Goes On

Psoriasis and Biologics: The Beat Goes On

Presented By
Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA
Conference
AAD 2019

With an increasing number of biologics to treat moderate-to-severe psoriasis, selection of the right drug becomes a real challenge for every dermatologist. Therapy should be guided by comorbidities but also by individual patient preferences. Novel drugs are not only more effective but also safer than conventional immunosuppressive drugs.

At present, there are numerous treatment possibilities for psoriasis. But does one choose the right agent? Selection of therapy has to take comorbidities into account. “The first question, I ask my patients is, do you have joint pain?” said Prof. Mark Lebwohl (Mount Sinai School of Medicine, USA) [1]. All tumour necrosis factor alpha (TNF-α) blockers are also effective in psoriatic arthritis (PsA). Other treatment possibilities are ustekinumab, apremilast, and the IL-17 blockers secukinumab, ixekizumab, and brodalumab.

Higher risk of non-melanoma skin cancer with TNF-alpha blockers

The correlation between t...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on